Adamis Pharma Stock Jumps After Naloxone Injection Under FDA Review For Opioid Overdose

  • The FDA has accepted for review Adamis Pharmaceuticals Corporation's ADMP marketing application seeking approval for Zimhi, a naloxone injection for opioid overdose.
  • The agency's target action date is November 12.
  • The company resubmitted the application in May after it received a complete response letter in November 2020.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: ADMP shares are up 11.9% at $1.13 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralBriefsOpioids
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!